Case Report
HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the Literature
Table 1
Summary of clinical characteristics of 48 patients with HHV8-negative effusion lymphomas of B-cell lineage.
| Characteristics | Number of patients (%) |
| Age (n = 48) | | Age > 60 | 10 (20.8) | Age < 60 | 38 (79.2) | Sex (n = 48) | | Male | 29 (60.4) | Female | 19 (39.6) | EBV status (n = 47) | | Positive | 10 (21.3) | Negative | 37 (78.7) | HCV status (n = 36) | | Positive | 8 (22.2) | Negative | 28 (77.8) | Site(s) involved (n = 41) | | Pleura | 27 (65.9) | Peritoneum | 16 (39.0) | Pericardium | 15 (36.6) | Treatment (n = 48) | | No chemotherapy | 17 (35.42) | CHOP | 11 (22.92) | CHOP + R | 3 (6.25) | THP-CVP | 6 (12.5) | THP-CVP + R | 4 (8.3) | Other regimens | 6 (12.5) | Unknown | 1 (2.0) | Outcome | | At 6 months (n = 45) | | Dead | (10/45) 22.2% | Alive | (35/45) 77.8% | At 1 year () | | Dead | (14/36) 38.9% | Alive | (22/36) 61.1% |
|
|
Abbreviations: CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; R: Rituximab; THP-CVP-pirarubicin, cyclophosphamide, vincristine, prednisone; EBV: Epstein-Barr virus, HCV: hepatitis C virus.
|